display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L2 - all populationmNSCLC - L2 - PDL1 positive
avelumab based treatment
avelumab alone JAVELIN Lung 200 ... JAVELIN Lung 200 ...

Study type: